IKZF1 and diffuse large B-cell lymphoma: CC-122 (Avadomide) has demonstrated substantial anti-proliferative activity across various DLBCL subgroups, surpassing lenalidomide in efficacy.333 This CELMoD uniquely degrades IKZF1 and boosts interferon-stimulated genes, enhancing tumoricidal activities333,334 and modulating the immune response by increasing PD-L1 expression.